The Registrar/CEO, Medical Laboratory Science Council of Nigeria (MLSCN), Dr Tosan Erhabor has expressed the willingness of the Council to consider the proposal of Codix Pharma Ltd – and indigenous pharmaceutical firm -on capacity building for Medical Laboratory practitioners.The Registrar made the remarks during the courtesy visit of the firm to MLSCN, on Tuesday, September6, 2022 in Abuja.
While noting that Codix Pharma was instrumental to the MLSCN acclaimed contributions to fight against the COVID – 19 pandemic, in line with international best practices, Erhabor added: “Your Company supported us to serve the country effectively during such a period of emergency. For the same company to also indicate interest in collaborating with MLSCN to build capacity for medical laboratory practitioners is very commendable, showing that you have the interest of the citizens at heart.We welcome the proposal.” According to him, “MLSCN attaches importance to capacity building as a means of achieving efficiency and effectiveness in the health sector, so we’re willing to collaborate with you to achieve such a laudable goal.”

Earlier in his remarks, Dr Babatunde Ipaye, a former health commissioner in Ogun State and consultant to Codix, explained that the team was at MLSCN in furtherance of the cordial relationship existing between the two organizations. According to him, the company’s decision to collaborate with MLSCN on capacity building for Medical Laboratory practitioners was in line with its corporate social responsibility (CSR) policy. “Our CSR vision is to help uplift the country. Codix is seeking backward integration in In-vitro Diagnostics (IVD) and would soon be opening the first indigenous IVD manufacturing plant in the country. As you may also recall, our products were the first to get a W.H.O approval globally, so we are serious about Quality. We commend your leadership and commitment towards improving the health of the citizens,” he said while adding that Codix would soon roll out malaria and other kits and would work with MLSCN in that regard.